0001209191-23-007782.txt : 20230208 0001209191-23-007782.hdr.sgml : 20230208 20230208162204 ACCESSION NUMBER: 0001209191-23-007782 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230206 FILED AS OF DATE: 20230208 DATE AS OF CHANGE: 20230208 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Jorgensen Nathan D. CENTRAL INDEX KEY: 0001842523 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39979 FILM NUMBER: 23599361 MAIL ADDRESS: STREET 1: C/O VOR BIOPHARMA INC. STREET 2: 100 CAMBRIDGEPARK DRIVE, SUITE 400 CITY: CAMBRIDGE STATE: MA ZIP: 02140 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vor Biopharma Inc. CENTRAL INDEX KEY: 0001817229 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 CAMBRIDGEPARK DRIVE STREET 2: SUITE 101 CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: 617-655-6580 MAIL ADDRESS: STREET 1: 100 CAMBRIDGEPARK DRIVE STREET 2: SUITE 101 CITY: CAMBRIDGE STATE: MA ZIP: 02140 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-06 0 0001817229 Vor Biopharma Inc. VOR 0001842523 Jorgensen Nathan D. C/O VOR BIOPHARMA INC. 100 CAMBRIDGEPARK DRIVE, SUITE 101 CAMBRIDGE MA 02140 0 1 0 0 Chief Financial Officer Common Stock 2023-02-06 4 A 0 45500 0.00 A 160769 D Employee Stock Option (right to buy) 5.55 2023-02-06 4 A 0 91000 0.00 A 2033-02-05 Common Stock 91000 91000 D Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning February 6, 2023, subject to the Reporting Person's continued service as of each such date. The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 6, 2023, in each case subject to the Reporting Person's continued service as of each such date. /s/ Rich Segal, Attorney-in-Fact 2023-02-08